Personalised Medicine

ETH Zurich molecular biologist Mandy Boontanrart is researching gene therapies that could be used to cure two of the most common types of inherited anaemia. She has now developed a promising approach for so-called beta-hemoglobinopathies.

Researchers at PSI have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug is now being tested on patients in the PROGNOSTICS project. A research consortium consisting of the Paul Scherrer Institute, the University Hospital Basel and ETH Zurich is receiving two million Swiss francs in funding for this project.

Despite approved treatments being available, multiple myeloma remains incurable. But researchers at ETH Zurich and University Hospital Zurich set out to improve treatment outcomes by testing hundreds of existing therapeutics outside the body to predict their effectiveness.

The LOOP Zurich research centre is creating a central platform for the exchange of health data between the University of Zurich, ETH Zurich and the four university hospitals. This will allow data to be utilised quickly and easily to the benefit of patients. 

New research offers potential benefits for those affected by the hereditary metabolic disease methylmalonic aciduria. By combining the results of multiple molecular analyses, scientists can better diagnose this rare and severe disease. In the future, an improved understanding of the disease might also improve treatment options.

Scientists led by EPFL have successfully engrafted breast cancer cells on mice, allowing them to study in vivo the cross-talk between the estrogen and progesterone receptors that hampers hormone therapies. Their findings suggest that endocrine therapy may need to be personalized, and that abrogating progesterone receptor expression can be a therapeutic option.